Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.65 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | CYP11B1 | P15538 | 12/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28148550 | 0.98 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL152870 | 0.96 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL27891018 | 0.91 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL803150 | 0.88 | RAB9A (0.69) | NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL22048403 | 0.87 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL14879788 | 0.85 | SMN1; SMN2 (0.67) | NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL15964146 | 0.85 | CYP11B1 (0.56) | NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL18174631 | 0.84 | RAB9A (0.56) | NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL31280939 | 0.83 | RAB9A (0.56) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL7563886 | 0.83 | RAB9A (0.56) | NPC1RAB9ASMN1; SMN2MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250338370-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | UNIVERSAL DISPLAY CORPORATION (US) | 2025-10-30 | — | — | US | disclosed |
| US-12408242-B2 | Heteroleptic iridium complexes as dopants | UNIVERSAL DISPLAY CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240138251-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | UNIVERSAL DISPLAY CORPORATION (US) | 2024-04-25 | — | — | US | disclosed |
| US-11910700-B2 | Heteroleptic iridium complexes as dopants | UNIVERSAL DISPLAY CORPORATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240025934-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230345811-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230303601-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230287011-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-09-14 | — | — | US | disclosed |
| US-7759489-B2 | Transition metal complex compound and organic electroluminescence device using the compound | IDEMITSU KOSAN CO., LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
| WO-2007119600-A9 | CARBAZOLE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007119600-A1 | CARBAZOLE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | WO | disclosed |
| US-20070176540-A1 | Transition metal complex compound and organic electroluminescence device using the compound | IDEMITSU KOSAN CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303601-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | MGLL, SELENOI, APOL1 | NPC1 3111/4885RAB9A 2676/4885SMN1; SMN2 2372/4885 |
| US-12408242-B2 | Heteroleptic iridium complexes as dopants | JUND, DRD2, DRD1 | NPC1 946/4885RAB9A 1245/4885SMN1; SMN2 3320/4885 |
| US-20240025934-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | SSB, RO60, LIFR | NPC1 4672/4885RAB9A 560/4885SMN1; SMN2 4178/4885 |
| US-20070176540-A1 | Transition metal complex compound and organic electroluminescence device using the compound | TMCO1, TIMCC, EMC2 | NPC1 3521/4885RAB9A 2555/4885SMN1; SMN2 3908/4885 |
| US-20250338370-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | JUND, DRD2, DRD1 | NPC1 946/4885RAB9A 1245/4885SMN1; SMN2 3320/4885 |
| US-20230287011-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OXGR1, OCIAD1 | NPC1 3285/4885RAB9A 1311/4885SMN1; SMN2 3545/4885 |
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCB1, SLC47A1 | NPC1 124/4885RAB9A 495/4885SMN1; SMN2 4857/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | NPC1 2922/4885RAB9A 2273/4885SMN1; SMN2 3084/4885 |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | PTGER1, PTGIR, PTGDR2 | NPC1 2415/4885RAB9A 3159/4885SMN1; SMN2 4658/4885 |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRM1 | NPC1 3553/4885RAB9A 1672/4885SMN1; SMN2 2910/4885 |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A2, GUCY1A1 | NPC1 2757/4885RAB9A 1349/4885SMN1; SMN2 1171/4885 |
| US-20240138251-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | JUND, DRD2, DRD1 | NPC1 946/4885RAB9A 1245/4885SMN1; SMN2 3320/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | NPC1 39/4885RAB9A 320/4885SMN1; SMN2 1943/4885 |
| US-20230345811-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OPRD1, L1CAM, OPRM1 | NPC1 1706/4885RAB9A 1045/4885SMN1; SMN2 2191/4885 |
| US-11910700-B2 | Heteroleptic iridium complexes as dopants | JUND, DRD2, DRD1 | NPC1 946/4885RAB9A 1245/4885SMN1; SMN2 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.